Recruiting
Phase 1

OnVagus

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07700212

Conditions

Metastatic Pancreatic Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Transcutaneous LFVB (tLFVB)

Study Details

Brief summary:

The goal of this clinical research study is to learn about the safety and tolerability of the OnVagus device when used by patients who have metastatic pancreatic cancer and are receiving chemotherapy.

Conditions

Metastatic Pancreatic Adenocarcinoma

Study ID

NCT07700212

Start date

Sep 25, 2026

Status verified date

Nov, 2026

Completion date

Dec 30, 2028

Anticipated

Primary completion date

Dec 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with metastatic pancreatic cancer.
  • Must have adenocarcinoma component (presence of combined histology is acceptable, as long as adenocarcinoma is present).
  • Weight loss from baseline of at least 5% (Baseline weight can be anytime from diagnosis onward).
  • Must have a tissue-based confirmation of diagnosis available. Tissue does not need to be a metastasis; primary tumor or prior surgery are acceptable sources.
  • Must have had progression of disease after one prior line of therapy in the metastatic setting.
  • Must be receiving or plan to receive another line of therapy in the metastatic setting. o If therapy is being administered outside MD Anderson, the patient is still eligible for this trial. o Enrollment onto a therapeutic clinical trial as this second line therapy is not explicitly excluded.
  • Must have triple ECG results available. Patients will be ineligible if they present: o Second- or third-degree block.

  • Prolonged QT wave.
  • Atrial fibrillation or flutter.
  • Uncontrolled ventricular fibrillation or flutter.
  • Premature ventricular contractions (PVC).

Exclusion Criteria:

Exclusion Criteria

  • History of cervical vagotomy on the right side of neck.
  • Known structural abnormalities on the right side of neck, including but not limited to situs inversus, bulky R-neck lymphadenopathy, etc., that in the investigators' opinion would lead to inability to correctly place the device onto the vagus nerve.
  • Implanted electrical device that passes through the neck (e.g.: cranial implant with battery pack in chest, and wires running through the neck).
  • Metal implants in the neck, including the cervical spine.
  • Recent (6 months or less) nerve block or botox injections to the head or neck.
  • Pain specifically localized to the treatment area, the right side of the neck.
  • Prior severe cerebrovascular disease (e.g., intracranial aneurysm, intracranial hemorrhage, stroke).
  • Prior severe cardiac disease, including but not limited to coronary artery disease (CAD), prior myocardial infarction (MI), uncontrolled congestive heart failure (CHF).

Study Design

Enrollment

10 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment with OnVagus device

Device will be applied by participant/caregiver daily for 30 min/day for 4 weeks; if well tolerated, 30 min twice per day for the following 4 weeks.

Interventions

Transcutaneous LFVB (tLFVB)

The transcutaneous LFVB (tLFVB), involves placing a superficial, transcutaneous device over the right vagus nerve. The device can be self-applied, after participant/provider education on application is completed. While applied, the device provides the low frequency vagal blockade intended to arrest the cachexia process.

Primary outcome measure

  • Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts and Locations

Central contacts

Locations

UT MD Anderson

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Brandon G. Smaglo, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.